ReviewVascular health and risk management2009
The use of sibutramine in the management of obesity and related disorders: an update.
Review in Vascular health and risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Efficacy and safety of ephedra-containing oral medications: a systematic review, meta-analysis, and exploratory dose-response analysis for weight reduction.Frontiers in pharmacology · 2024Pooled it
- Antidepressants for polycystic ovary syndrome.The Cochrane database of systematic reviews · 2013Pooled it
- Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway.Endocrine reviews · 2025Review
- Novel Therapeutic Approach for Obesity: Seaweeds as an Alternative Medicine with the Latest Conventional Therapy.Medical sciences (Basel, Switzerland) · 2024Review
- Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).Archives of endocrinology and metabolism · 2024Review
- Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment.Postepy psychiatrii neurologii · 2023Review
- Serine Threonine-Protein Kinase-Derived IW13 Improves Lipid Metabolism via C/EBP-α/SREBP1/FAS Signaling Pathways in HFD-Induced Zebrafish In Vivo Larval Model.Applied biochemistry and biotechnology · 2023Article
- Obesity pillars roundtable: Phentermine - Past, present, and future.Obesity pillars · 2022Article
- Anti-Obesity Effect ofNutrients · 2020Article
- Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.Future medicinal chemistry · 2020Review
- Molecular networking aided metabolomic profiling of beet leaves using three extraction solvents and in relation to its anti-obesity effects.Journal of advanced research · 2020Article
- Antiobesity Activities of Methanolic Extracts ofEvidence-based complementary and alternative medicine : eCAM · 2017Article
- Natural Dietary and Herbal Products in Anti-Obesity Treatment.Molecules (Basel, Switzerland) · 2016Review
- Plants with potential use on obesity and its complications.EXCLI journal · 2015Review
- Nonalcoholic fatty liver disease and cardiovascular disease.World journal of gastroenterology · 2014Review
- Therapeutic options for binge eating disorder.Eating and weight disorders : EWD · 2013Review
- Sibutramine effects on central mechanisms regulating energy homeostasis.Current neuropharmacology · 2012Article
- Assessing gene-gene interactions in pharmacogenomics.Molecular diagnosis & therapy · 2012Review
- Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study.BMJ open · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders. METHODS AND
resultsThe most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on the lipid profile (mainly triglycerides and high density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for up to one year. Preliminary studies showed that sibutramine may also improve other obesity-associated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge eating disorder and adolescent obesity. The high discontinuation rates and some safety issues mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, it has not yet been established that treatment with sibutramine will reduce cardiovascular events and total mortality.
conclusionsSibutramine, in conjunction with lifestyle measures, is a useful drug for reducing body weight and improving associated cardiometabolic risk factors and obesity-related disorders. Studies of longer duration are required to determine the precise indications of the drug, to evaluate safety issues and to assess its efficacy on cardiovascular mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.